Cargando…
PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428783/ http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10 |
| _version_ | 1785090552380784640 |
|---|---|
| author | Palandri, Francesca Gröpper, Stefanie Loschi, Michael Bellesso, Marcelo Grosicki, Sebastian Giraldo, Pilar Harrison, Claire Clevenger, Tracy Stuart, Nikki Qamoos, Hope Vosganian, Gregory Rothbaum, Wayne P. Verstovsek, Srdan Vachhani, Pankit |
| author_facet | Palandri, Francesca Gröpper, Stefanie Loschi, Michael Bellesso, Marcelo Grosicki, Sebastian Giraldo, Pilar Harrison, Claire Clevenger, Tracy Stuart, Nikki Qamoos, Hope Vosganian, Gregory Rothbaum, Wayne P. Verstovsek, Srdan Vachhani, Pankit |
| author_sort | Palandri, Francesca |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428783 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104287832023-08-17 PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) Palandri, Francesca Gröpper, Stefanie Loschi, Michael Bellesso, Marcelo Grosicki, Sebastian Giraldo, Pilar Harrison, Claire Clevenger, Tracy Stuart, Nikki Qamoos, Hope Vosganian, Gregory Rothbaum, Wayne P. Verstovsek, Srdan Vachhani, Pankit Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428783/ http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Palandri, Francesca Gröpper, Stefanie Loschi, Michael Bellesso, Marcelo Grosicki, Sebastian Giraldo, Pilar Harrison, Claire Clevenger, Tracy Stuart, Nikki Qamoos, Hope Vosganian, Gregory Rothbaum, Wayne P. Verstovsek, Srdan Vachhani, Pankit PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_full | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_fullStr | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_full_unstemmed | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_short | PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) |
| title_sort | pb2198: trial in progress: an open-label, global, multicenter, phase 1b/2 study of tl-895, a bruton’s tyrosine kinase inhibitor (btki), added to ruxolitinib (rux) in patients (pts) with myelofibrosis (mf) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428783/ http://dx.doi.org/10.1097/01.HS9.0000975544.01102.10 |
| work_keys_str_mv | AT palandrifrancesca pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT gropperstefanie pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT loschimichael pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT bellessomarcelo pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT grosickisebastian pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT giraldopilar pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT harrisonclaire pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT clevengertracy pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT stuartnikki pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT qamooshope pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT vosganiangregory pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT rothbaumwaynep pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT verstovseksrdan pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf AT vachhanipankit pb2198trialinprogressanopenlabelglobalmulticenterphase1b2studyoftl895abrutonstyrosinekinaseinhibitorbtkiaddedtoruxolitinibruxinpatientsptswithmyelofibrosismf |